Sumitomo Pharma Co., Ltd.

Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Oncology, Inc.

Tomoyuki Furuta

Hiroyuki Kitano

Kazuto Mori

Hajime Seki

Yohei Kobayashi

Chiang Jia Li

Hitoshi Ban

Seiji Kamioka

Yuki Fujii

Keiji Adachi

Yoko Nakai

Shoukou Ri

Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein Xrepresents CRor N, Xrepresents CRor N, Xrepresents CRor N, Xrepresents CRor N, Y represents optionally substituted Calkyl, an optionally substituted Calicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted Caryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R, R, R, and Reach independently represent a hydrogen atom, halogen, cyano, optionally substituted Calkyl, optionally substituted Calkoxy, or the like.

2-heteroaryl aminoquinazolinone derivative

Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): 

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein Xrepresents CR or N, Xrepresents CRor N, Xrepresents CRor N, Y represents an optionally substituted Caryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted Caryl, Rrepresents a hydrogen atom, halogen, cyano, optionally substituted Calkyl sulfonyl, optionally substituted Calkyl, or optionally substituted Calkoxy, and R, R, and Rindependently represent a hydrogen atom, halogen, optionally substituted Calkyl, or optionally substituted Calkoxy] or a pharmaceutically acceptable salt thereof.

2-aminoquinazolinone derivative

This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N&#x2014;R; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; Rand Rare each independently a hydrogen atom, a halogen atom, or an optionally-substituted Calkyl carbonyl group, etc.; R, Rand Rare each independently a hydrogen atom, a halogen atom, or an optionally-substituted Calkyl carbonyl group, etc.; and Ris a hydrogen atom or an optionally-substituted Calkyl group, etc.]. 

Tricyclic quinone derivative

The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like. 

8-oxodihydropurine derivative

Growing community of inventors

Osaka, Japan

Tomoyuki Furuta